Immucell (ICCC) Net Cash Flow (2010 - 2025)
Immucell's (ICCC) quarterly Net Cash Flow came in at -$79367.0 in Q4 2025, down 57.47% YoY from -$186618.9 in Q4 2024, and up 96.24% on a QoQ basis from -$2.1 million in Q3 2025.
Immucell (ICCC) Net Cash Flow (2010 - 2025) Analysis & Trends
Immucell (ICCC) has 16 years of Net Cash Flow data on file, last reported at -$79367.0 in Q4 2025.
- Quarterly Net Cash Flow fell 57.47% year-over-year to -$79367.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $48599.0 (down 98.25% YoY) and the FY2025 annual result came in at $48599.0, down 98.25% from the prior year.
- Net Cash Flow grew to -$79367.0 in Q4 2025, from -$2.1 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $3.9 million in Q2 2021 to a low of -$3.0 million in Q4 2022.
- A 5-year average of -$157155.3 and a median of -$111327.0 in 2021 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 981.81% — and 2025, when it jumped 4672.9%.
- Tracing ICCC's Net Cash Flow over 5 years: stood at -$310291.0 in 2021, then tumbled by 878.5% to -$3.0 million in 2022, then jumped by 66.71% to -$1.0 million in 2023, then jumped by 95.01% to -$50401.0 in 2024, then plunged by 57.47% to -$79367.0 in 2025.
- The last three Net Cash Flow figures came in at -$79367.0 (Q4 2025), -$2.1 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Immucell | 95.12 Mn | 86.26 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -79,367.00 |
| Dec 31, 2025 | -79,367.00 |
| Sep 30, 2025 | -2.11 Mn |
| Sep 30, 2025 | -2.11 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.40 Mn |
| Mar 31, 2025 | 841,139.00 |
| Mar 31, 2025 | 841,139.00 |
| Dec 31, 2024 | -50,401.00 |
| Dec 31, 2024 | -50,401.00 |
| Sep 30, 2024 | 2.48 Mn |
| Sep 30, 2024 | 2.48 Mn |
| Jun 30, 2024 | 363,938.00 |
| Jun 30, 2024 | 363,938.00 |
| Mar 31, 2024 | -18,394.00 |
| Mar 31, 2024 | -18,394.00 |
| Dec 31, 2023 | -1.01 Mn |
| Dec 31, 2023 | -1.01 Mn |
| Sep 30, 2023 | 535,151.00 |
| Sep 30, 2023 | 535,151.00 |